Clinical Trial Update: Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update assessing the safety (adverse events) and preliminary activity of ABBV-383 given by subcutaneous injection in adults with relaps…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ABBV-383 (Etentamig)

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING